Unknown

Dataset Information

0

Short and Long Term Clinical and Immunologic Follow up after Bone Marrow Mesenchymal Stromal Cell Therapy in Progressive Multiple Sclerosis-A Phase I Study.


ABSTRACT: Bone marrow derived mesenchymal stromal cells (BM-MSCs) have emerged as a possible new therapy for Multiple Sclerosis (MS), however studies regarding efficacy and in vivo immune response have been limited and inconclusive. We conducted a phase I clinical study assessing safety and clinical and peripheral immune responses after MSC therapy in MS. Seven patients with progressive MS were intravenously infused with a single dose of autologous MSC (1-2 × 106 MSCs/kg body weight). The infusions were safe and well tolerated when given during clinical remission. Five out of seven patients completed the follow up of 48 weeks post-infusion. Brain magnetic resonance imaging (MRI) showed the absence of new T2 lesions at 12 weeks in 5/6 patients, while 3/5 had accumulated new T2 lesions at 48 weeks. Patient expanded disability status scales (EDSS) were stable in 6/6 at 12 weeks but declined in 3/5 patients at 48 weeks. Early changes of circulating microRNA levels (2 h) and increased proportion of FOXP3+ Tregs were detected at 7 days post-infusion compared to baseline levels. In conclusion, MSC therapy was safe and well tolerated and is associated with possible transient beneficial clinical and peripheral immunotolerogenic effects.

SUBMITTER: Iacobaeus E 

PROVIDER: S-EPMC6947442 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Short and Long Term Clinical and Immunologic Follow up after Bone Marrow Mesenchymal Stromal Cell Therapy in Progressive Multiple Sclerosis-A Phase I Study.

Iacobaeus Ellen E   Kadri Nadir N   Lefsihane Katia K   Boberg Erik E   Gavin Caroline C   Törnqvist Andrén Anton A   Lilja Anders A   Brundin Lou L   Blanc Katarina Le KL  

Journal of clinical medicine 20191202 12


Bone marrow derived mesenchymal stromal cells (BM-MSCs) have emerged as a possible new therapy for Multiple Sclerosis (MS), however studies regarding efficacy and in vivo immune response have been limited and inconclusive. We conducted a phase I clinical study assessing safety and clinical and peripheral immune responses after MSC therapy in MS. Seven patients with progressive MS were intravenously infused with a single dose of autologous MSC (1-2 × 10<sup>6</sup> MSCs/kg body weight). The infus  ...[more]

Similar Datasets

| S-EPMC4449093 | biostudies-literature
| S-EPMC6186266 | biostudies-literature
| S-EPMC7867148 | biostudies-literature
| S-EPMC4857408 | biostudies-literature
2019-02-12 | PXD011643 | Pride
| S-EPMC5005173 | biostudies-literature
| S-EPMC4275011 | biostudies-literature
| S-EPMC5405000 | biostudies-literature
| S-EPMC8456218 | biostudies-literature
| S-EPMC9327419 | biostudies-literature